MAGEA10 is a cancer/testis antigen normally expressed in testis and placenta but aberrantly expressed in multiple human malignancies 1. Its intrinsically disordered N-terminal domain, particularly a unique seven-amino acid linear motif (PRAPKR), governs its expression, nuclear localization, and anomalous protein migration 2. Mechanistically, MAGEA10 increases histone acetylation by stabilizing histone acetyltransferases KAT2A and KAT2B, preventing their degradation through p62-mediated autophagy and antagonizing E3 ubiquitin ligase-mediated ubiquitination 3. This creates a positive feedback loop where KAT2A enhances MAGEA10 transcription, contributing to tumorigenesis. Clinically, MAGEA10 expression correlates with poor prognosis across multiple cancers, including gastric cancer (predicting early hepatic recurrence with 58.3% sensitivity and 84.5% specificity) 4, pancreatic cancer (associated with chemoresistance) 5, and breast DCIS (associated with invasive recurrence) 6. As a cancer-specific antigen, MAGEA10 represents a promising immunotherapy target; HLA-A*0201-restricted peptides have been identified for presentation 1, and MAGEA10-specific T cell receptors demonstrate cytotoxic activity against HCC cells 7. Multi-antigen DNA vaccines targeting MAGEA10 alongside other MAGEA isoforms show efficacy against chemoresistant tumors 5.